Clinical reference Biomarker Directory
Back to directory

Anti-Scl-70

Established

Anti-Scl-70 is a specific marker for diffuse systemic sclerosis, associated with higher interstitial lung disease risk.

Also known as Anti-Scl-70 anti-topoisomerase I antibody
In plain language

This antibody is a specific marker for a more severe, widespread form of scleroderma, a disease that hardens skin and connective tissue. Testing positive raises particular concern for lung involvement, so doctors watch lung function especially closely in these patients.

Biomarker & context

Anti-Scl-70 (anti-topoisomerase I) antibodies target a nuclear enzyme and are a specific serologic marker for diffuse cutaneous systemic sclerosis (scleroderma), completing the classic scleroderma/myositis antibody panel alongside the SS-A/Ro and SS-B/La antibodies already covered in this biomarker set.

What it indicates

Positive anti-Scl-70 supports a diffuse systemic sclerosis diagnosis and is associated with higher risk of interstitial lung disease and more extensive skin involvement compared to the anti-centromere antibody pattern, which instead points toward limited disease.

Diagnosis & clinical testing

Measured via immunoassay (ELISA) as part of an extractable nuclear antigen (ENA) panel, typically ordered alongside anti-centromere antibody and ANA testing when scleroderma is clinically suspected based on skin changes, Raynaud's phenomenon, or unexplained interstitial lung disease.

Guiding treatment

Anti-Scl-70 positivity supports closer pulmonary surveillance (baseline and serial pulmonary function testing, high-resolution CT) given the associated interstitial lung disease risk, which is a leading cause of mortality in systemic sclerosis and a key driver of treatment intensity decisions.

Clinical significance

Positivity prompts closer pulmonary surveillance given the strong association with lung involvement and mortality risk.

References
  1. General rheumatology reference literature on anti-Scl-70/anti-topoisomerase I antibody in diffuse systemic sclerosis.